OverviewSuggest Edit

Meridian Bioscience is a life science company which develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The Company offers testing platforms and technologies. These products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens.The Company also provides bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies.

TypePublic
Founded1977
HQCincinnati, US
Websitemeridianbioscience.com
Employee Ratings2

Latest Updates

Employees (est.) (Sep 2018)585(-8%)
Job Openings25
Revenue (FY, 2018)$213.6 M(+7%)
Share Price (Jun 2019)$11.5 (+3%)

Meridian Bioscience Office Locations

Meridian Bioscience has offices in Cincinnati, Memphis, London, Schijndel and in 5 other locations
Cincinnati, US (HQ)
3471 River Hills Dr
Memphis, US
5171 Wilfong Road
Eveleigh, AU
Suite G16A, NIC Building Australian Technology Park
Braine-l'Alleud, BE
2 Avenue du Japon
Paris, FR
34 Rue de Ponthieu
Luckenwalde, DE
3 Im Biotechnologiepark
Show all (9)

Meridian Bioscience Financials and Metrics

Meridian Bioscience Revenue

Embed Graph
View revenue for all periods
Meridian Bioscience's revenue was reported to be $213.57 m in FY, 2018
USD

Revenue (Q3, 2019)

48.4m

Gross profit (Q3, 2019)

28.3m

Gross profit margin (Q3, 2019), %

58.3%

Net income (Q3, 2019)

5.1m

EBIT (Q3, 2019)

6.5m

Market capitalization (10-Jun-2019)

491.9m

Closing stock price (10-Jun-2019)

11.5

Cash (30-Jun-2019)

55.2m

EV

512.6m
Meridian Bioscience's current market capitalization is $491.9 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

188.7m188.8m194.8m196.1m200.8m213.6m

Revenue growth, %

0%3%1%

Cost of goods sold

67.6m71.6m72.9m68.3m75.9m83.1m

Gross profit

121.0m117.2m121.9m127.8m124.8m130.5m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

44.8m50.1m47.2m48.0m51.5m48.2m47.2m51.3m50.7m46.8m54.1m50.1m52.3m56.5m51.7m51.5m50.2m48.4m

Cost of goods sold

16.8m18.5m18.0m18.8m19.0m17.9m15.6m17.7m17.8m17.4m20.6m18.9m20.5m21.9m19.8m19.9m20.9m20.2m

Gross profit

28.0m31.6m29.2m29.2m32.5m30.3m31.6m33.6m32.9m29.5m33.5m31.2m31.8m34.6m32.0m31.6m29.3m28.3m

Gross profit Margin, %

63%63%62%61%63%63%67%65%65%63%62%62%61%61%62%61%58%58%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

44.3m43.0m50.0m47.2m57.1m59.8m

Accounts Receivable

Inventories

34.8m35.5m35.8m45.1m41.5m42.0m

Current Assets

114.1m112.7m122.9m126.8m133.9m139.1m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

43.7m38.2m39.3m49.5m42.7m46.0m53.4m48.9m45.8m49.3m54.7m55.3m54.7m56.4m57.9m61.5m66.1m55.2m

Inventories

37.7m38.1m37.6m34.4m33.0m33.6m38.8m41.9m43.4m44.7m42.4m40.9m43.6m43.8m45.2m41.9m40.9m43.3m

Current Assets

111.2m114.0m113.5m114.7m116.5m118.0m123.2m128.2m126.9m126.0m128.8m129.2m136.6m139.5m140.2m139.6m144.7m137.4m

Goodwill

23.4m23.5m23.8m22.6m22.1m22.8m22.1m64.5m63.7m60.7m60.8m54.6m55.0m55.4m54.8m54.4m54.6m90.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

38.0m34.7m35.5m32.2m21.6m23.8m

Inventories

41.5m(1.1m)

Accounts Payable

7.7m4.1m

Cash From Operating Activities

44.4m38.3m42.8m37.2m41.4m34.8m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

7.4m17.7m26.6m7.9m10.1m27.1m8.9m18.0m26.7m6.3m15.6m15.8m6.3m11.6m18.4m8.1m15.2m20.3m

Inventories

33.6m38.8m41.9m43.4m44.7m42.4m(2.4m)(2.4m)(4.1m)(37.0k)832.0k(67.0k)

Accounts Payable

5.5m7.2m7.9m7.4m7.5m6.4m1.3m3.7m3.0m(4.1m)(1.3m)(1.7m)

Cash From Operating Activities

13.6m23.6m31.2m12.1m18.5m26.0m13.0m25.1m32.5m5.2m13.8m23.6m9.4m21.0m28.3m
USDY, 2019

EV/EBIT

68.3 x

EV/CFO

15.6 x

Financial Leverage

1.7 x
Show all financial metrics

Meridian Bioscience Online and Social Media Presence

Embed Graph

Meridian Bioscience News and Updates

Meridian Bioscience to Hold Third Quarter 2019 Financial Results Conference Call on July 30, 2019

CINCINNATI, July 10, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report third quarter 2019 financial results Tuesday, July 30, 2019.

Meridian Bioscience Announces Closing of Transaction to Acquire Business of GenePOC

CINCINNATI, June 03, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has completed its previously announced acquisition of the business of GenePOC Inc., a Quebec City, Quebec, Canada ba…

Meridian Bioscience Reports Second Quarter 2019 Operating Results, Suspends Quarterly Cash Dividend, and Provides Fiscal 2019 Guidance for Pending Acquisition

CINCINNATI, April 30, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter and first six months ended March 31, 2019.

Meridian Bioscience Announces Agreement to Acquire Business of GenePOC; Adds State-of-the-Art Molecular Diagnostics Platform

CINCINNATI, April 30, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has entered into a definitive agreement to acquire the business of GenePOC Inc., a Quebec City, Quebec, Canada base…

Meridian Bioscience to Hold Second Quarter 2019 Financial Results Conference Call on April 30, 2019

CINCINNATI, April 10, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report second quarter 2019 financial results Tuesday, April 30, 2019.

Meridian Bioscience Announces Preliminary Second Quarter 2019 Revenue Results; Updates Fiscal 2019 Guidance

CINCINNATI, April 02, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided a business update including preliminary sales results for its second fiscal quarter and revised financial guidance for …
Show more

Meridian Bioscience Blogs

Meridian Bioscience Reports Third Quarter 2019 Operating Results

Meridian Bioscience Reports Third Quarter 2019 Operating Results Content Import Tue, 07/30/2019 - 07:30 Meridian Bioscience Reports Third Quarter 2019 Operating Results July 30, 2019 at 7:30 AM EDT This release is a backfill from a News Wire Ear…

Meridian Bioscience Frequently Asked Questions

  • When was Meridian Bioscience founded?

    Meridian Bioscience was founded in 1977.

  • How many employees does Meridian Bioscience have?

    Meridian Bioscience has 585 employees.

  • What is Meridian Bioscience revenue?

    Latest Meridian Bioscience annual revenue is $213.6 m.

  • What is Meridian Bioscience revenue per employee?

    Latest Meridian Bioscience revenue per employee is $365.1 k.

  • Who are Meridian Bioscience competitors?

    Competitors of Meridian Bioscience include Varex Imaging, Horizon Discovery and Definiens.

  • Where is Meridian Bioscience headquarters?

    Meridian Bioscience headquarters is located at 3471 River Hills Dr, Cincinnati.

  • Where are Meridian Bioscience offices?

    Meridian Bioscience has offices in Cincinnati, Memphis, London, Schijndel and in 5 other locations.

  • How many offices does Meridian Bioscience have?

    Meridian Bioscience has 9 offices.